Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8N490
UPID:
PNKD_HUMAN
Alternative names:
Myofibrillogenesis regulator 1; Paroxysmal nonkinesiogenic dyskinesia protein; Trans-activated by hepatitis C virus core protein 2
Alternative UPACC:
Q8N490; A8K1F2; Q96A48; Q9BU26; Q9NSX4; Q9ULN6; Q9Y4T1
Background:
Probable hydrolase PNKD, also known as Myofibrillogenesis regulator 1, plays a pivotal role in muscle function and movement regulation. It is implicated in Dystonia 8, a disorder characterized by involuntary muscle contractions and abnormal postures triggered by stress or stimulants. This protein's alternative names include Paroxysmal nonkinesiogenic dyskinesia protein and Trans-activated by hepatitis C virus core protein 2, reflecting its diverse biological implications.
Therapeutic significance:
The association of PNKD with Dystonia 8, where it aggravates cardiac hypertrophy via the NF-kappa-B signaling pathway, highlights its potential as a therapeutic target. Understanding the role of PNKD could open doors to potential therapeutic strategies for managing and treating involuntary muscle contractions and related cardiovascular complications.